By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: Wegovy (semaglutide) activates one hormone receptor; Zepbound (tirzepatide) activates two. That extra pathway tends to produce more weight loss in Zepbound's favor, but Wegovy currently holds an FDA cardiovascular-risk approval that Zepbound doesn't yet have — and Wegovy now comes in a daily pill, not just a weekly injection.
Both of these medications get compared constantly because they occupy the same space: FDA-approved, once-weekly injectable treatments for chronic weight management. But they're different drugs with different mechanisms, different approval histories, and — as of recent FDA actions — different available formulations. Here's what the data actually shows.
Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist. Zepbound is the brand name for tirzepatide, a dual GLP-1/GIP receptor agonist — meaning it activates a second hormone receptor (GIP) that Wegovy doesn't touch at all.
Both are approved by the FDA as an adjunct to reduced-calorie diet and increased physical activity for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have at least one weight-related health condition. Wegovy is additionally approved for adolescents 12 and older with obesity.
As of 2026, Wegovy is available in three forms:
Zepbound, by contrast, is currently available only as a once-weekly injection, in dose strengths ranging from 5 mg to 15 mg. There's no FDA-approved oral tirzepatide formulation. If a daily pill instead of a weekly injection matters to you, that's currently a Wegovy-only option.
This is where the mechanism difference shows up directly in the data.
Wegovy (STEP-1 trial): In a 68-week trial of 1,961 adults with obesity or overweight, semaglutide 2.4 mg produced a mean weight loss of 14.9% of starting body weight.
Zepbound (SURMOUNT-1 trial): In a 72-week trial of 2,539 adults, tirzepatide produced up to 20.9% mean weight loss at its highest dose, with 57% of participants losing at least 20% of their starting weight.
Head-to-head data: A direct comparison trial put both drugs against each other at their maximum approved doses over 72 weeks. Participants on tirzepatide (Zepbound) lost about 50 pounds on average (20.2% of starting weight), compared to about 33 pounds (13.7%) on semaglutide (Wegovy). More people on tirzepatide reached 25% or greater total weight loss.
A broader systematic review comparing the two drug classes found tirzepatide at its higher doses (10 mg, 15 mg) produced roughly 4–5.4% more weight loss than semaglutide's approved dose — a pattern that's held up consistently across academic meta-analyses.
This is a meaningful distinction that often gets missed in side-by-side comparisons: Wegovy has an FDA-approved cardiovascular risk-reduction indication that Zepbound does not currently have.
Wegovy's cardiovascular approval is based on the SELECT trial — a large outcomes study of over 17,000 adults with overweight or obesity and established cardiovascular disease, but without diabetes. The trial found roughly a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) compared to placebo. Based on this data, Wegovy (both the injection and the newer oral pill) carries an approved indication specifically for reducing cardiovascular risk in adults with obesity or overweight who already have heart disease.
Zepbound's current labeling is focused on chronic weight management. As of its most recent FDA label, it does not yet carry a separate cardiovascular outcomes approval, though SURMOUNT trial data has shown improvements in related cardiometabolic markers like blood pressure and lipids, and further outcome studies are ongoing.
Practically: if cardiovascular risk reduction alongside weight loss is a specific priority — particularly for someone who already has diagnosed heart disease — that's currently a distinction in Wegovy's favor at the regulatory level, independent of which drug produces more weight loss on average.
As with other GLP-1 and dual-agonist comparisons, the side effect profiles of Wegovy and Zepbound are dominated by the same gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion are the most commonly reported effects for both. Both carry the same boxed warning for thyroid C-cell tumors seen in animal studies and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Both labels also carry warnings for pancreatitis, gallbladder disease, and acute kidney injury (often related to dehydration from GI symptoms). Zepbound's label additionally notes a hypoglycemia risk when combined with insulin or certain other diabetes medications.
Indirect comparisons suggest tirzepatide at its higher doses may produce somewhat fewer GI side effects than semaglutide at its approved dose — meaning Zepbound's edge in average weight loss doesn't appear to come at the cost of meaningfully worse tolerability.
Both medications start well below their target dose and increase gradually:
Starts at 0.25 mg weekly, increasing every 4 weeks (0.5 mg → 1.0 mg → 1.7 mg) to the 2.4 mg maintenance dose. Wegovy HD follows a similar escalation pattern toward the higher 7.2 mg dose.
Starts at 1.5 mg once daily, increasing roughly every 30 days through intermediate doses toward the 25 mg daily maintenance dose.
Starts at 2.5 mg weekly, increasing in 2.5 mg increments roughly every 4 weeks (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) toward the target maintenance dose.
The exact pace — and whether to hold at a lower dose longer — is a decision a prescriber makes based on how well someone tolerates each increase.
Q: Is Zepbound stronger than Wegovy?
It's not a matter of strength but of mechanism — Zepbound activates an additional hormone receptor (GIP) that Wegovy doesn't. Across trials, this has translated to more average weight loss with Zepbound, but "stronger" doesn't capture the full picture, especially given Wegovy's cardiovascular approval.
Q: Which one should I ask my doctor about?
That depends on your specific health history, prior response to either drug class, and priorities — including whether cardiovascular risk reduction, formulation (pill vs. injection), insurance coverage, or maximum average weight loss matters most to you. This is a conversation for a licensed prescriber, not something to decide from a comparison article.
Q: Does Zepbound have a pill version?
Not currently. As of the latest FDA labeling, Zepbound is available only as a weekly injection. Wegovy is the only one of the two with an approved oral option.
Q: Is Wegovy's cardiovascular benefit exclusive to people with heart disease?
The FDA-approved indication specifically applies to adults with obesity or overweight who already have established cardiovascular disease. It's not a general cardiovascular-prevention claim for anyone taking the drug.
Q: Are the side effects meaningfully different between the two?
Not dramatically — both are dominated by the same GI symptoms. Some data suggests tirzepatide (Zepbound) may cause slightly fewer GI side effects at its higher doses relative to semaglutide (Wegovy), but for most people the experience is broadly similar.
See also: Semaglutide vs. Tirzepatide for a deeper look at the mechanism difference between these two drug classes, and Oral vs. Injectable GLP-1 for how Wegovy's pill and injection options compare on trial results.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizTirzepatide activates one more hormone receptor than semaglutide — and across every major trial, that difference shows up as more average weight loss.
Wegovy and Ozempic both contain semaglutide — but they're approved for different uses, dosed differently, and covered differently by insurance.
GLP-1 medications explained in plain language: what they are, how they work in your gut and brain, and what the research shows about weight loss results.